Collaboration with Zealand Pharma Advances to Phase II

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/DiabetesThe dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim ’s pipeline portfolio in obesity and diabetesThe Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will trigger a EUR 20 million milestone payment to Zealand Pharma out of total outstanding potential milestone payments of EUR 365 million and high single to low double digit royalties on future sales
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news